Posted by Michael Wonder on 14 Mar 2022
Corium receives FDA approval of Adlarity (donepezil transdermal system) for treatment of patients with Alzheimer's disease
14 March 2022 - First and only once weekly patch for convenient, well-tolerated delivery of most used drug for treatment of Alzheimer's related dementia.
Corium announced today the U.S. FDA has approved Corium's Adlarity (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type.
